J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports
Johnson & Johnson (NYSE:JNJ) is in advanced talks to acquire privately held eye disease drug developer Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter.
The deal could involve an upfront cash payment of $2.2 billion and up to $1.2 billion in milestone payments, although discussions could still fall apart, the report said.
Ollin, backed by Arch Venture Partners and Mubadala Capital, is developing OLN324, a drug targeting wet age-related macular degeneration and diabetic macular oedema, two leading causes of severe vision loss. The treatment is expected to enter late-stage clinical trials.
The acquisition would expand J&J's presence in retinal disease treatments, an area where it has limited exposure despite its contact lens business.
The potential deal comes amid a record year for biotech acquisitions, with 46 companies valued at more than $1 billion sold so far, surpassing the previous annual record of 35, according to investment bank Stifel, the FT reported.